Increased Drug Resistance
2
Pipeline Programs
5
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
1 programChange in Ocular Flora Resistance From Repeated Topical Antibiotic UseN/A1 trial
Active Trials
NovartisBASEL, Switzerland
1 programChange in Ocular Flora Resistance From Repeated Topical Antibiotic UseN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Hanmi PharmaceuticalNOV120101
SandozChange in Ocular Flora Resistance From Repeated Topical Antibiotic Use
Clinical Trials (2)
Total enrollment: 240 patients across 2 trials
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Start: Jan 2013Est. completion: Sep 201440 patients
Phase 2Completed
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
Start: Jun 2010Est. completion: Dec 2011200 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.